Recently, complications in patients with nontransfusion-dependent thalassemia (NTDT), in particular those with b-thalassemia intermedia (b-TI), were found to be significantly different from those in patients with transfusion dependent thalassemia (TDT), mainly b-thalassemia major (b-TM).
These include a-thalassemia; Hemoglobin (Hb) H disease, caused by deletions of three out of four normal a-globin genes (deletional Hb H disease) or an interaction of two linked a-globin deletions with a missense mutation known as nondeletional Hb H disease. 5, 6 The most common genotype of the latter is Hb Constant Spring (Hb CS) due to a termination codon mutation of the a2-globin genes. In addition, a specific variation at codon 26 of the b-globin gene, known as Hb E, can cause an aberrant b-globin chain that consequently alters physical and biochemical properties from normal b A globin chains, and can interact with b-thalassemia allele leading to Hb E/b-thalassemia syndrome (Hb E/b-thal). 7 This condition has a wide variation of clinical presentation and severity; on one end, patients could be as severe as b-TM and require regular blood transfusions. However, on another end, Hb E/ b-thal patients could be very mild with lesser anemia and would seldom require blood transfusions. Due to unclear clinical classification in the past, several severe Hb E/b-thal patients have been treated similarly to b-TI patients with splenectomy and infrequent blood transfusions. To this regard, it was obvious that these severe thalassemia patients were inadequately treated and several thalassemia related complications have been reported. [8] [9] [10] [11] [12] To provide a better classification for thalassemia that could embrace all common thalassemia syndromes into a simple, phenotypebased categorization, a new classification for thalassemia based on their transfusion requirements or dependency has been proposed into "transfusion dependent thalassemia" (TDT) and "nontransfusiondependent thalassemia" (NTDT). 13 With this new classification, two recent clinical practice guidelines for TDT 14 and NTDT 15 were developed by Thalassemia International Federation. We recently published about this new classification and related clinical diagnosis in a review elsewhere. 16 Several complications linked to chronic anemia and ineffective erythropoiesis including iron overload, endocrinopathies, especially diabetes mellitus (DM), extramedullary hematopoiesis (EMH), chronic leg ulcer, pulmonary hypertension (PHT), and thrombosis and so forth have long been observed in patients with thalassemia syndromes. 17 Due to improving management of patients with TDT by regular blood transfusions and iron chelation therapy, these complications have decreased significantly in recent years. 18 In contrary, a cohort study of TI patients has shown terrifying evidence that b-TI patients representing NTDT had a much higher incidence of several thalassemia related complications compared to b-TM who were well-treated. 19, 20 This finding was consistent with several studies from Mediterranean countries, the Middle East, and Indian subcontinents. [21] [22] [23] [24] However, there were limited data of the prevalence of thalassemia related complications in NTDT from Southeast Asian populations and none was a prospective study.
Anecdotally several NTDT patients were managed by splenectomy. This is one of the treatments of choice in patients with TI who have growth retardation, poor health, symptomatic splenomegaly, or require massive transfusion treatment. Recently, Taher et al. from the "OPTI-MAL CARE" study showed that the patients with b-TI who have been splenectomized had a higher rate of complications such as EMH, thrombosis, PHT, DM, and heart failure compared to the nonsplenectomized group. 19 The mechanisms of these complications in splenectomized patients have been summarized and discussed earlier. 25 However, there is no prospective study on different entities of NTDT patients apart from b-TI, and the effects of splenectomy on other types of NTDT remain unknown.
To provide a true prevalence of thalassemia related complications in our Thai NTDT patients, we prospectively evaluated our NTDT patients who were mainly Hb E/b-thal and Hb H disease. We comprehensively collected demographic data and determined their possible complications using current standard clinical and laboratory evaluations during their regular visits to our thalassemia clinics. In addition, we analyzed for clinical risk factors, including the effect of splenectomy, upon these clinical complications to bestow further insight on optimal management and care for our Southeast Asian NTDT patients. 
| Study design
This was a single-center, outpatient based, prospective cross-sectional study in our cohort of NTDT patients at Thalassemia clinic, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand during their regular routine visits.
| Assessments
A prospective review of the medical charts, medical interview, and physical examination were performed for all patients. Data was collected, including demographics, splenectomy status (splenectomized or nonsplenectomized), significant medical history, history of iron chelation, average Hb (g/dL), steady-state serum ferritin levels (ng/mL), and all other available laboratory records (see Table 1 ). Their history of blood transfusion status was evaluated and divided into 3 groups as follows: (1) never transfused group, (2) occasional transfusion; those who required transfusions for transient severe anemia due to infection, surgery, or pregnancy, and (3) frequent (regular) transfusion; those with frequent interval transfusions every 1-3 months during the period of hypersplenism (prior to splenectomy, if being splenectomized).
To document current thalassemia related complications, several laboratory parameters/imaging studies were conducted as determined by the definitions and methods as shown in Supporting Information Table S1 in a prospective manner. These include abdominal ultrasonography, radiologic examination, echocardiography, magnetic resonance imaging (MRI) using T2* analysis for determining liver iron concentration (LIC), hormonal evaluations, and bone mineral density by DEXA scan and so forth. All evaluations were performed using standard techniques as described by the manufacturers. For MRI evaluation, we used the techniques recently reported by our group that have been standardized and validated. 27 Based on history of splenectomy, patients were categorized into 2 groups, splenectomized and nonsplenectomized groups. For splenectomized groups, laboratory parameters were divided into presplenectomy and postsplenectomy (if prior data was available). At least 2 independent measurements, obtained during steady state (e.g., nonacute transient hemolysis for presplenectomy stage) and within 6 months prior to the study period, were averaged for each laboratory parameter. All patients have been regularly followed in our hospital over 10 years.
| Statistical analysis
Baseline characteristics of all patients were shown in Figure S1 ). Most of patients received occasional transfusions (80.7%). There was a non-significant difference in ferritin level (median 1,745, 848, and 959 ng/mL, respectively, P 5 .09), highest in splenectomized Hb E/b-thal and lowest
in Hb H disease. However, there were no significant differences in Table S1 ).
Hb E/b-thal indicates Hb E/b-thalassemia; Hb H, Hb H disease; NA, not applicable.
number of subjects with iron overload (serum ferritin > 800 ng/mL or LIC > 5 mg/g dry weight liver) or history of iron chelation (Table 1) .
| Thalassemia related complications
Thalassemia related complications in this study population were listed in Table 2 nonsplenectomized Hb E/b-thal and Hb H disease patients (100%, 63.2%, 52.2%, respectively, P 5 .007, Table 2 ). Also, EMH was more prevalent in Hb E/b-thal patients compared to other groups (P 5 .038, Table 2 ).
Using univariate analyses (Supporting Information Table S2) , a lower Hb level (Hb < 9 g/dL) and splenectomy were associated with gallstones (P 5 .01 and .001, respectively), while higher ferritin level (>1,000 ng/mL), transfusion therapy, and iron chelation therapy were associated with liver transaminitis (P 5 .001, .016, and .034, respectively). EMH indicates extramedullary hematopoiesis, PHT, pulmonary hypertension. a Number (%). b P-value for determination of the difference between 3 patient groups. c Echocardiogram was performed only in selected cases (n 5 38), especially those with iron overload. There were 3 missing cases in splenectomized Hb E/b-thal group with iron overload (serum ferritin levels during study period were 485, 890, and 1235 ng/mL, respectively). Also, three additional echocardiograms were tested in noniron overload splenectomized cases during study period, in which 1 case in splenectomized group had been worked up due to pitting edema and cardiomegaly and was diagnosed as mild pulmonary HT (Hb E/b 0 thalassemia, female 32 year-old, splenectomized 1 year prior due to huge splenomegaly, Hb 6-6.5 g/dL).
By multivariate logistic regression analyses (Supporting Information

FIGURE 1
Comparison of thalassemia related complications (in percentage; %) found in our study population, Hb E/b-thalassemia and Hb H disease, and results from the OPTIMAL CARE study (b-thalassemia intermedia). 19 Of note, the mean age of patients in our study was 41. 
| D I SCUSSION
Our prospective cohort study comprehensively compared the complications in Thai NTDT patients with Hb E/b-thal vs Hb H disease, with higher prevalence of gallstones and EMH in the former group. Our prevalence of each complication is slightly different from those of a previous study of NTDT from Chiang Mai University, which found higher rates of EMH, abnormal liver function, and endocrinopathies and lower rates of cholelithiasis and osteoporosis. 28 However, the major differences between our study and the previous study are the prospective nature of our study and a more comprehensive evaluation of our NTDT patients in an unbiased manner. Nevertheless, within the same complications such as osteoporosis and abnormal liver function, they found advanced age and serum ferritin to be a significant risk factors similar to our study, 28 consistent with another previous study. 19 The effect of iron siderosis in the liver has long been established, and we further confirmed that the levels of iron overload as presented by serum ferritin were associated with increased ALT, representing liver toxicity due to redox activity of iron overload. 29 In our study, advanced age, but not female gender, was associated with increased rates of osteoporosis (P 5 .033 vs .537, respectively, Supporting Information Table S2 ). We used low bone mass (osteopenia and osteoporosis) for multivariate analysis and found that a higher ferritin (>1000 ng/mL) was significantly associated with low bone mass (RR 5 4.6, P 5 .043) and higher Hb (>9 g/dL) was protective for low bone mass (RR 5 0.07, P 5 .031, data not shown). Low bone mass has a complex nature involving several factors including vitamin D status, calcium intake, levels of osteoclast activity, iron overload, and history of iron chelation. 30 Recently, our group reported that low bone mass can develop as early as prepubertal and pubertal age in NTDT patients, and baseline Hb level was associated with low bone mass. This further confirms that these two risk factors (age and Hb) are consistent from two independent studies.
Notably from our study, all NTDT patients who underwent splenectomy were found to have gallstones (Table 2 ). This may suggest higher hemolytic levels in those who required splenectomy resulting in lower baseline Hb levels and higher prevalence of gallstones. This could be a consequence of disease severity itself rather than the effect of transfusion therapy, as there was no difference in gallstones between 3 transfusion groups (P 5 .89, Supporting Information Table S2 ). Finally, average Hb was lower in Hb H disease with gallstones than those without gallstones similar to the groups of splenectomized and nonsplenectomized Hb E/b thal (data not shown). Therefore, our data suggests that higher Hb level (Hb > 9 g/dL) should be protective against gallstones. Recently, a new pharmacological compound has been proposed to be effective for both TDT and NTDT. The activin ligand trapper (luspatercept and sotatercept) has been demonstrated to increase Hb by 1-2 g/dL in NTDT patients. [31] [32] [33] To this regard, our data could be used to set up a target Hb level to prevent several complications in NTDT patients.
In addition, maintaining baseline Hb > 9 g/dL might reduce chance of splenectomy. From our study, splenectomy was shown to be the only significant risk factor for serious bacterial infection (RR 5 15.1) similar to other study. 34 Therefore, avoiding splenectomy should reduce unnecessarily risks including serious overwhelming infections, PHT, thrombosis, and leg ulcer. 19 Comparing our data to the OPTIMAL CARE study, 19 our results were quite different in several aspects, including the prevalence of each complication (Figure 1 ). Baseline characteristics in our patients were slightly female predominant, higher proportion of older age group (> 35 years old), different types of thalassemia (including the coinheritance of both a-and b-thalassemia, not present in the OPTIMAL CARE study), and possibly less transfusion support received (lower mean average Hb) compared to the previous study. 19 Comparing the studies, our data showed a lower rate of EMH, which could be explained by technique(s) used for diagnosis, as most EMH in our study were asymptomatic and detected by plain film. However, if a more sensitive technique such as computed tomography (CT scan) and/or ultrasonography had been used, the prevalence of EMH might be higher than that reported here.
Interestingly, our data showed a higher rate of gallstones and PHT compared to the OPTIMAL CARE study (68.4% vs 17% for gallstones and 15.8% (all NTDT) vs 11% for PHT). 19 If we compared between Hb E/b-thal from our study with b-TI from the OPTIMAL CARE study, the incidence of PHT would be 20.8% vs 11%. This suggests that our patients might receive inadequate transfusion support, leading to a higher rate of hemolysis. It has been shown that a higher rate of splenectomy could also lead to increased risk of PHT, 35, 36 however, we did not see this association in our study. Conversely, we showed lower thrombotic events compared to those of the OPTIMAL CARE study (1.8% vs 14%). In general, the incidence of thrombosis in the general population of Southeast Asia, and in particular in Thailand, is relatively lower than in Caucasian or Middle East populations. [37] [38] [39] Although the majority of our NTDT patients have been splenectomized, this factor might be balanced with other thrombotic risk factors such as ethnicity, the use of contraception, and inherited thrombophilia, which are lower in our population. [37] [38] [39] Nevertheless, Taher et al., has reported a median time to thrombosis after splenectomy to be approximately 8 years, 40 while in our cohort it was only 4 years (range 1-38 years). This might be partly responsible for a lower prevalence of thrombosis in our study.
As the coinheritance of an a-globin defect can ameliorate the severity of a b-thalassemia phenotype (and vice versa) due to more balanced globin synthesis, 7,41 we compared Hb H disease with or without Hb E to elucidate the effect of co-inheritance of a-globin mutation and hemoglobinopathy on these complications. Interestingly, we could not fully demonstrate an impact of this interaction on ameliorating longterm complications due to a limited number of cases and lack of complete genetic analysis. This requires further study to demonstrate whether this complex globin abnormality (Hb H disease with Hb E) might be more severe than we would expect from their genetic
interactions. In addition, we found that deletional Hb H disease had a less severe phenotype than nondeletional Hb H disease (Hb H/CS disease) in terms of thalassemia related complications.
The major limitation of our study is a relatively low number of NTDT patients who were comprehensively evaluated. This was due to several reasons. Most NTDT patients were not regularly followed in our clinics earlier in their disease course, as most presented after they developed anemic symptoms or developed complications that required medical attention. This is true not only for Thailand, but also many countries throughout Asia (Vip Viprakasit, personal communication).
Moreover, all evaluations described in the methodology session demanded several hospital visits for tests and imaging studies, and many NTDT patients denied to be enrolled since they could not see their own personal benefit. However, our data provided, for the first time, a true prevalence of each NTDT related complication, particularly
in Hb E/b thal and Hb H disease. These results should alert all clinicians to be aware and help educate all future NTDT patients of their need to be completely evaluated, as these complications can cause clinical consequences that hamper their quality of life. With better awareness in both physicians and patients, a larger cohort with a higher number of NTDT patients will be possible.
In conclusion, our NTDT patients have a different genotype from those of the previous NTDT study (mainly b-TI), several complications related to NTDT were prevalent and related to the same risk factors, such as baseline Hb levels, iron overload, and the status of splenectomy.
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